The upcoming Phase 3 trial of RG6042 will test whether lowering the levels of a mutant form of huntingtin…
Articles by José Lopes, PhD
A method called quantitative electroencephalography (qEEG) enables the identification of Huntington’s gene carriers and could become a disease…
Although well-tolerated, the investigational treatment Huntexil (pridopidine) failed to improve motor functions in a year-long Phase 2 clinical trial…
Measuring concentrations of mutant huntingtin (mHTT) protein and another protein, called neurofilament light protein (NfL), can provide early and specific…
A Georgetown University Medical Center (GUMC) Phase 1b clinical trial is recruiting patients to test the safety and tolerability…
Two new clinical studies of Roche’s investigational therapy RG6042 for Huntington’s disease (HD) are planned to start by the end…
Immunotherapy candidate laquinimod failed to meet its primary objective of improving motor function in Huntington’s disease patients after 12 months…
Targeting specific genes involved in inflammation and cellular structure may be a therapeutic strategy to reduce protein clumps in patients…
A key protein in Huntington’s disease has damaging effects on heart function beyond the disease’s devastating neurological impact, according…
Treatment with investigational medication VX15/2503 halts disease-related loss of brain volume and improves its metabolic activity in Huntington’s disease patients,…